A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study

Autor(es)

Martins-de-Souza, Daniel ^{[1, 2, 3]} ; Guest, Paul C. ^[1] ; Steiner, Johann ^{[4, 5, 6]}

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Lab Neuroprote, Dept Biochem & Tissue Biol, Inst Biol, RuaMonteiroLobato 255, BR-13083862 Campinas, SP - Brazil

^[2] Conselho Nacl Desenvolvimento Cient & Tecnol CNPq, Inst Nacl Biomarcadores Neuropsiquiatr INBION, Sao Paulo - Brazil

^[3] UNICAMP Neurobiol Ctr, Campinas - Brazil

^[4] Univ Magdeburg, Dept Psychiat & Psychotherapy, Magdeburg - Germany

^[5] Univ Magdeburg, Lab Translat Psychiat, Magdeburg - Germany

^[6] CBBS, Magdeburg - Germany

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE; v. 270, n. 1, p. 127-134, FEB 2020.
• Citações Web of Science: 0

Resumo

A major hurdle faced by most schizophrenia patients is the poor efficacy of current antipsychotic medications. This stems from a poor understanding of the underlying pathophysiology and the lack of biomarkers for the prediction of a positive medication response. By employing state-of-the-art proteomic analysis of blood plasma from 58 patients who were either drug-naive or drug-free at the time of sample collection, we identified potential biomarkers that were predictive of a positive response after 6 weeks of treatment with antipsychotics. Complement and coagulation cascades were the most over-represented biological pathways among these proteins, consistent with the importance of these processes in schizophrenia. Although preliminary, these findings are novel and may drive future efforts in the development of predictive tests for medication efficacy and thereby have a positive influence on disease outcome. (AU)

• Processo FAPESP: 17/25588-1 - Da compreensão básica a biomarcadores clínicos para a esquizofrenia: um estudo multidisciplinar centrado na neuroproteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 13/08711-3 - Desenvolvimento de um teste preditivo para medicação bem sucedida e compreensão das bases moleculares da esquizofrenia através da proteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores